138 related articles for article (PubMed ID: 21040764)
1. A novel, simple method to simulate gelling process of injectable biodegradable in situ forming drug delivery system based on determination of electrical conductivity.
Wang K; Jia Q; Yuan J; Li S
Int J Pharm; 2011 Feb; 404(1-2):176-9. PubMed ID: 21040764
[TBL] [Abstract][Full Text] [Related]
2. Effect of polymer type on the dynamics of phase inversion and drug release in injectable in situ gelling systems.
Liu H; Venkatraman SS
J Biomater Sci Polym Ed; 2012; 23(1-4):251-66. PubMed ID: 21244721
[TBL] [Abstract][Full Text] [Related]
3. In situ-forming pharmaceutical organogels based on the self-assembly of L-alanine derivatives.
Couffin-Hoarau AC; Motulsky A; Delmas P; Leroux JC
Pharm Res; 2004 Mar; 21(3):454-7. PubMed ID: 15070096
[TBL] [Abstract][Full Text] [Related]
4. Exploring the potential of N-methyl pyrrolidone as a cosurfactant in the microemulsion systems.
Bachhav YG; Date AA; Patravale VB
Int J Pharm; 2006 Dec; 326(1-2):186-9. PubMed ID: 16949777
[TBL] [Abstract][Full Text] [Related]
5. A novel flunarizine hydrochloride-loaded organogel for intraocular drug delivery in situ: Design, physicochemical characteristics and inspection.
Dai M; Bai L; Zhang H; Ma Q; Luo R; Lei F; Fei Q; He N
Int J Pharm; 2020 Feb; 576():119027. PubMed ID: 31953090
[TBL] [Abstract][Full Text] [Related]
6. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of 12-HSA-based organogels as injectable implants for the controlled delivery of hydrophilic and lipophilic therapeutic agents.
Esposito CL; Tardif V; Sarrazin M; Kirilov P; Roullin VG
Mater Sci Eng C Mater Biol Appl; 2020 Sep; 114():110999. PubMed ID: 32993979
[TBL] [Abstract][Full Text] [Related]
8. Preparation and in vitro evaluation of a pluronic lecithin organogel containing ricinoleic acid for transdermal delivery.
Boddu SH; Bonam SP; Wei Y; Alexander K
Int J Pharm Compd; 2014; 18(3):256-61. PubMed ID: 25306775
[TBL] [Abstract][Full Text] [Related]
9. Designing Solvent Exchange-Induced In Situ Forming Gel from Aqueous Insoluble Polymers as Matrix Base for Periodontitis Treatment.
Srichan T; Phaechamud T
AAPS PharmSciTech; 2017 Jan; 18(1):194-201. PubMed ID: 26951505
[TBL] [Abstract][Full Text] [Related]
10. Cosolvent effects on the drug release and depot swelling in injectable in situ depot-forming systems.
Liu H; Venkatraman SS
J Pharm Sci; 2012 May; 101(5):1783-93. PubMed ID: 22318766
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the erosion rate and the drug release kinetics from organogels designed as matrices for oral controlled release of a hydrophobic drug.
Pereira Camelo SR; Franceschi S; Perez E; Girod Fullana S; Ré MI
Drug Dev Ind Pharm; 2016; 42(6):985-97. PubMed ID: 26548427
[TBL] [Abstract][Full Text] [Related]
12. Solvent exchange-induced in situ forming gel comprising ethyl cellulose-antimicrobial drugs.
Phaechamud T; Mahadlek J
Int J Pharm; 2015 Oct; 494(1):381-92. PubMed ID: 26302862
[TBL] [Abstract][Full Text] [Related]
13. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process.
Kempe S; Metz H; Mäder K
J Control Release; 2008 Sep; 130(3):220-5. PubMed ID: 18611421
[TBL] [Abstract][Full Text] [Related]
14. Monitoring release of ketoprofen enantiomers from biodegradable poly(D,L-lactide-co-glycolide) injectable implants.
Wang SH; Liang ZH; Zeng S
Int J Pharm; 2007 Jun; 337(1-2):102-8. PubMed ID: 17296274
[TBL] [Abstract][Full Text] [Related]
15. An examination of the rheological and mucoadhesive properties of poly(acrylic acid) organogels designed as platforms for local drug delivery to the oral cavity.
Jones DS; Muldoon BC; Woolfson AD; Sanderson FD
J Pharm Sci; 2007 Oct; 96(10):2632-46. PubMed ID: 17702045
[TBL] [Abstract][Full Text] [Related]
16. Improved initial burst of estradiol organogel as long-term in situ drug delivery implant: formulation, in vitro and in vivo characterization.
Yang Y; Xu L; Gao Y; Wang Q; Che X; Li S
Drug Dev Ind Pharm; 2012 May; 38(5):550-6. PubMed ID: 22420863
[TBL] [Abstract][Full Text] [Related]
17. Formulation and evaluation of novel controlled release of topical pluronic lecithin organogel of mefenamic acid.
Jhawat V; Gupta S; Saini V
Drug Deliv; 2016 Nov; 23(9):3573-3581. PubMed ID: 27494650
[TBL] [Abstract][Full Text] [Related]
18. Solubility improvement of drugs using N-methyl pyrrolidone.
Sanghvi R; Narazaki R; Machatha SG; Yalkowsky SH
AAPS PharmSciTech; 2008; 9(2):366-76. PubMed ID: 18431671
[TBL] [Abstract][Full Text] [Related]
19. Poly(ethylene carbonate) as a surface-eroding biomaterial for in situ forming parenteral drug delivery systems: a feasibility study.
Liu Y; Kemmer A; Keim K; Curdy C; Petersen H; Kissel T
Eur J Pharm Biopharm; 2010 Oct; 76(2):222-9. PubMed ID: 20650316
[TBL] [Abstract][Full Text] [Related]
20. Injectable, in situ forming poly(propylene fumarate)-based ocular drug delivery systems.
Ueda H; Hacker MC; Haesslein A; Jo S; Ammon DM; Borazjani RN; Kunzler JF; Salamone JC; Mikos AG
J Biomed Mater Res A; 2007 Dec; 83(3):656-66. PubMed ID: 17514745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
